Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
For much of the world, the full promise of liquid biopsy exceeds purchasing power.
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
You may also be interested in...
The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.
In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.
The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has cleared an innovative test from life sciences company Karius that can detect more than 1,000 pathogens from all five classes.